Method Development and Validation Of Prasugrel Tablets By RP- HPLC

Similar documents
DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

Reverse Phase High Performance Liquid Chromatography method for determination of Lercanidipine hydrochloride in bulk and tablet dosage form

7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC.

A RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF PARA- PHENYLENEDIAMINE IN PURE FORM AND IN MARKETED PRODUCTS

Research Article METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF ELBASVIR AND GRAZOPREVIR BY RP-HPLC

Volume 6, Issue 2, January February 2011; Article-015

RP-HPLC Method Development and Validation of Dapagliflozin in Bulk and Tablet formulation

A Simple, Novel Validated Stability Indicating RP-HPLC method for estimation of Duloxetine HCl in Capsule Pharmaceutical Formulation

Validated RP-HPLC Method for Estimation of Cefprozil in Tablet Dosage Form

STABILITY INDICATING METHOD OF RELATED IMPURITIES IN VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE TABLETS

AND VALIDATION FOR SIMULTENEOUS ESTIMATION OF AMBROXOL HYDROCHLORIDE AND DOXOFYLLINE IN PHARMACEUTICAL DOSAGES FORMS AND BULK DRUGS BY RP-HPLC METHOD

Int. J. Pharm. Sci. Rev. Res., 30(2), January February 2015; Article No. 09, Pages: 63-68

Radhakrishnan K. et al. / International Journal of Pharmacy & Therapeutics, 3(1), 2012, e- ISSN Print ISSN

Stability indicating RP-HPLC method for determination of azilsartan medoxomil in bulk and its dosage form

International Journal of Pharmaceutical Research & Analysis

International Journal of Current Trends in Pharmaceutical Research. International Journal of Current Trends in Pharmaceutical Research

Chapter 4: Verification of compendial methods

Development and Validation of a HPLC Method for Determination of Anastrozole in Tablet Dosage Form

Impact factor: 3.958/ICV: 4.10 ISSN:

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

Pelagia Research Library

Journal of Pharmaceutical and Biomedical Analysis Letters. Analysis Letters

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD TO DETERMINE CINITAPRIDE HYDROGEN TARTARATE IN BULK AND PHARMACEUTICAL FORMULATION

METHOD DEVELOPMENT AND VALIDATION OF RALTEGRAVIR POTASSIUM AND RILPIVIRINE HCL BY HPLC AND HPTLC METHODS

Journal of Chemical and Pharmaceutical Research

Journal of Chemical and Pharmaceutical Research, 2012, 4(6): Research Article. Estimation of zaleplon by a new RP-HPLC method

Pelagia Research Library

International Journal of Pharmacy and Pharmaceutical Sciences Vol 2, Issue 1, 2010

Analytical Method Development and Validation of Lafutidine in Tablet dosage form by RP-HPLC

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

Dissolution study and method validation of alprazolam by high performance liquid chromatography method in pharmaceutical dosage form

Journal of Drug Delivery and Therapeutics

Available online at Scholars Research Library

Stability-indicating HPLC determination of tolterodine tartrate in pharmaceutical dosage form

Development And Validation Of Rp-Hplc Method For Determination Of Velpatasvir In Bulk

Validation of Stability-Indicating RP-HPLC Method for the Assay of Ibrutinib in Pharmaceutical Dosage form

INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND LIFE SCIENCES

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

Development and Validation of Stability Indicating RP-HPLC Method for the Determination of Anagrelide HCl in Pharmaceutical Formulation

Simultaneous Estimation of Residual Solvents (Isopropyl Alcohol and Dichloromethane) in Dosage Form by GC-HS-FID

Saudi Journal of Medical and Pharmaceutical Sciences

Analytical method development and validation of carvedilol in bulk and tablet dosage form by using uv spectroscopic method as per ich guidelines

Pelagia Research Library

Novus International Journal of Analytical Innovations 2012, Vol. 1, No. 3

Development And Validation Of Stability Indicating RP-HPLC Method For Estimation Of Ledipasvir And Sofosbuvir

Isocraticc Reverse Phase HPLC Method-Determination and Validation of Cilostazol

Development of Validated Analytical Method of Mefenamic Acid in an Emulgel (Topical Formulation)

Development and validation of RP-LC method for lisinopril dihydrate in bulk and its pharmaceutical formulations

Asian Journal of Research in Chemistry and Pharmaceutical Sciences Journal home page:

Development and Validation of Stability-Indicating RP-HPLC Method for Estimation of Atovaquone

Intercontinental journal of pharmaceutical Investigations and Research

Journal of Chemical and Pharmaceutical Research, 2017, 9(1): Research Article

Method Development and Validation for the Estimation of Darunavir in Rat Plasma by RP-HPLC

J Pharm Sci Bioscientific Res (4): ISSN NO

Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry Journal home page:

Simultaneous estimation of amitryptyline and chlordiazepoxide by RP-HPLC method

Method development and validation of Tinidazole and Ciprofloxacin HCl in bulk and tablet dosage form by Rp-HPLC

Asian Journal of Chemical and Pharmaceutical Research. Asian Journal of Chemical and Pharmaceutical Research

Liquid Chromatography and Spectroscopic Method for Estimation of Sulphadoxine in Marketed Formulation

Scholars Research Library. Rapid and sensitive RP-HPLC analytical method development and validation of Pioglitazone hydrochloride

Analytical method development and validation of gabapentin in bulk and tablet dosage form by using UV spectroscopic method

Sumathi Gracy et al. Int. Res. J. Pharm. 2014, 5 (4) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

Development and validation a RP-HPLC method: Application for the quantitative determination of quetiapine fumarate from marketed bulk tablets

KEYWORDS: Acetaminophen, Doxylamine succinate, Dextromethorphan hydrobromide.

Development and Validation of Stability Indicating Assay Method of Etodolac by using UV-Visible Spectrophotometer

Sravani and Haritha Indian Journal of Research in Pharmacy and Biotechnology ISSN: (Print) ISSN: (Online)

INDICATING LIQUID CHROMATOGRAPHIC METHOD FOR QUANTIFICATION OF CIPROFLOXACIN HCL, ITS RELEATED SUBSTANCE AND TINIDAZOLE IN TABLET DOSAGE FORM

VALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION

Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry Journal home page:

Validated HPLC Methods

CHAPTER - IV. Acharya Nagarjuna University, Guntur 105

STABILITY INDICATING RP HPLC METHOD FOR ANALYSIS OF DORZOLAMIDE HCl IN THE BULK DRUG AND IT S PHARMACEUTICAL DOSAGE FORM

SIMPLE AND SENSITIVE VALIDATED REVERSE PHASE HPLC-UV METHOD FOR THE DETERMINATION OF LYMECYCLINE IN PHARMACEUTICAL DOSAGE FORMS

Development and Validation of Sensitive RP-HPLC Method for the Estimation of Glibenclamide in Pure and Tablet Dosage Forms

DEVELOPMENT AND VALIDATION OF HPLC METHOD OF DISSOLUTION TEST FOR METOPROLOL SUCCINATE AND CILNIDIPINE

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF STABILITY- INDICATING ASSAY METHOD OF TICAGRELOR TABLETS BY USING RP-HPLC

ANALYTICAL METHOD PROCEDURES

INTERNATIONAL JOURNAL OF UNIVERSAL PHARMACY AND BIO SCIENCES

Available online Research Article

International Journal of Pharma Research and Health Sciences. Available online at

TEMPLATE FOR AN EXAMPLE STANDARD TEST METHOD

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF IVABRADINE HCL IN BULK AND FORMULATION

International Journal of Current Trends in Pharmaceutical Research. International Journal of Current Trends in Pharmaceutical Research

Research Article Available online at

Department of Quality Assurance, Luqman College of Pharmacy, GULBARGA (K.S.) INDIA ABSTRACT

RP-HPLC Method Development and Validation for Estimation of Triamcinolone Acetonide in Injectable Suspension using USP-Type-IV Dissolution Apparatus

DEVELOPMENT OF RP-HPLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE IN PHARMACEUTICAL DOSAGE FORMS

SIMULTANEOUS RP HPLC DETERMINATION OF CAMYLOFIN DIHYDROCHLORIDE AND PARACETAMOL IN PHARMACEUTICAL PREPARATIONS.

PHARMA SCIENCE MONITOR

Determination of Fexofenadine Hydrochloride in Pharmaceutical Dosage Form By Reverse Phase High Performance Liquid Chromatography Method

DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING RP-HPLC METHOD FOR ASSAY OF IRBESARTAN IN PURE AND PHARMACEUTICAL DOSAGE FORM

Simultaneous HPLC Determination of Methocarbamol, Paracetamol and Diclofenac Sodium

LC Determination of Deferasirox in Pharmaceutical Formulation

Chapter-4 EXPERIMENTAL WORK BY RP-HPLC

PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES

B. Anupama et al. IRJP 2 (1)

Department of Chemistry, JNTUACE, Kalikiri

RP-HPLC Estimation of Trospium Chloride in Tablet Dosage Forms

Pharmacophore 2011, Vol. 2 (4), ISSN Pharmacophore. (An International Research Journal)

International Research Journal of Pharmaceutical and Applied Sciences Available online at Int. Res J Pharm. App Sci.

Transcription:

Method Development and Validation Of Prasugrel Tablets By RP- HPLC K.Sonia*, Ndwabe Hamunyare, K.Manikandan Department of Pharmaceutical Analysis, SRM College of Pharmacy, SRM University, Kattankulathur, Kancheepuram Dist. 603 203, Tamil Nadu, India. Abstract: Prasugrel hydrochloride is a platelet inhibitor and anti-thrombosis drug 1. Mortality rate due to thrombosis has been rising and so the need to develop methods for the analysis of the drug. The scope of the study was development and validation of Prasugrel Hydrochloride 5mg tablet by RP-HPLC for precision, accuracy linearity and robustness. A RP-HPLC method was developed and validated for the estimation of Prasugrel Hydrochloride in tablet dosage form. A Zorbax, SB-Phenyl 250 4.6mm, 5μ in isocratic mode, with mobile phase containing buffer (ph 6.5 with Triethylamine and potassium dihydrogen ortho phosphate) Acetonitrile: Water (90:10) [40-60 (v/v)] was used. The flow rate was 1.2 ml/min and the analyte was monitored at 235 nm. The retention time for Prasugrel HCL was 11.5 minutes. The method was validated for system suitability, specificity, precision, accuracy, linearity, ruggedness and robustness. Linearity was obtained in the concentration range of 50ppm to 150ppm, with correlation coefficient of 0.999. The percentage recovery of Prasugrel was found to be in the range of 98%-102%. The method was robust and rugged as observed from insignificant variation in the results of analysis by changes in the flow rate and temperature separately and analysis being performed by different analyst, on different systems and by using different columns respectively. There was no interference due to excipients and mobile phase, the method was found was to be specific. The system suitability parameters were within limit, hence it was concluded that the system was suitable to perform the assay. Key words: Prasugrel Hydrochloride, Method development validation and RP-HPLC. INTRODUCTION Pharmaceutical analysis plays a vital role in the quality assurance and quality assurance of drugs. Qualitative analysis reveals the chemical identity of the sample, whilst quantitative analysis establishes the relative amount of the species. High Performance Liquid Chromatography is one of the most common methods of analysis for pharmaceuticals 2. HPLC is a type of liquid chromatography that employs a liquid mobile phase and a very finely divided stationary phase. The HPLC method is a method of choice for analytical chemistry because it can yield the required results in a specific, robust, linear, precise and accurate way. Other advantages to this method are that it is a very quick method (speed), greater resolution, improved resolution, and re-usable columns, ideal for substances of low viscosity, easy sample recovery and maintenance. In normal phase chromatography, the stationary phase is a polar adsorbent, whilst the mobile phase is a mixture of the non-aqueous solvents 3. In new method development a good strategy should be employed as many experimental runs are required in order to achieve the desired results. Important factors to consider in order obtaining reliable analysis results are careful sample preparation and careful sample preparation, appropriate column choice and appropriate operating conditions 4. Also the performance of the recording and data handling systems should be reliable. Most importantly the developed method should be validated. Validation parameters for High performance liquid chromatography include system suitability, accuracy, specificity, linearity, precision, limit of quantitation, limit of detection and robustness. According to the USP, system suitability tests are done to verify that the resolution and reproducibility of the system that is to be analysed are adequate it is generally hinged on the fact that the analytical operations, the equipment, electronics and samples are part of an integral system which can be evaluated as a whole 5. ICH defines selectivity as a method which provides responses for many or a number of chemical entities which may not, or may be distinguished from each other. Specificity on the other hand refers to that method which produces a response for only one analyte. Accuracy refers to a measure of how close the values of the experiment are to the true value. Sensitivity is also very important and it defines the ability to detect very small variations in the concentration of the sample analyte. Precision measures the closeness of data values to each other under the same experimental conditions. Reproducibility then defines precision between laboratories. A linear relationship should exist between samples and assays. Limit of detection defines the lowest concentration of an analyte that can be detected in a sample, whilst the limit of quantitation defines that concentration that can be quantified under the given set of conditions. Finally robustness defines that capability to remain unaffected by small deliberate variations in the parameters of the method. These parameters are very important in the development of an analytical procedure 6. No method has been documented therefore for the analysis of Prasugrel tablets using the Reverse HPLC method. Prasugrel Hydrochloride is an antithrombotic drug, mainly used to treat acute coronary syndrome in those patients that are undergoing percutaneous coronary intervention, angina, atherosclerosis and other few conditions. MATERIALS AND METHODS Acetonitrile, Potassium dihydrogen ortho phosphate, Triethyl amine and purified water were used are of HPLC Grade. Prasugrel Hydrochloride Marketed Formulation- 1133

Prax 05 was procured from (MSN LABS). The instrument used is weighing balance (Sartorius), ph metre (Polmon), Sonicator (fast clean), HPLC (Agilent Technologies 1200 Series). Selection of Suitable mobile phase, diluent and wave length: The mobile phase solution A is prepared by dissolving 1.36 g of Potassium Dihydrogen orthophosphate in 100ml of water and mix. Adjusted ph to 6.5 with triethylamine. Filtered and degassed the solution. The Solution B: Degassed mixture of acetonitrile and water in the ratio 90:10. The wavelength is 235nm and the mobile phase ratios for Solution A: Solution B is (40:60) The Chromatographic conditions: The experiment is carried out using column (Inertsil C18, 5 m, 150 mm x 4.6 mm) to Zorbax SB-Phenyl 250 x 4.6mm, 5µ at Flow rate of 1.0ml/min using detector wave length of 235nm, column temperature used is ambient, injection volume is 10µl, run time of 25 minutes. Table 1: Data of System Suitability parameter Injection RT Peak Area USP Plate USP Count tailing 1 11.647 2147703 7945 1.217 2 11.640 2145329 7965 1.202 3 11.560 2148786 8011 1.207 4 11.645 2146980 8022 1.200 5 11.640 2149104 7900 1.208 Mean 11.6264 2147580 7968 1.207 SD 0.037246 1518.2 %RSD 58.132 1357.87 Table 2: System Suitability Observed System Suitability value Theoretical Plate for Should be NLT 9562 Prasugrel Std 1 2500 Tailing factor for Prasugrel Should be 1.20 Std 1 NMT 2.0 RSD for peak area for Should be Prasugrel for five injection of 0.07 NMT 2.0% Std 1 Similarity factor between two 1.001 0.985 to 1.015 Prasugrel Std preparation Fig 1: Retention Time has increased. RESULTS & DISCUSSIONS The developed method was within limits. The results have also shown that the excipients and the mobile phase did not affect the validation parameters. This therefore showed that there was no interference due to these parameters and therefore it can be concluded that the method was specific. System suitability was also proven as every value was within the recommended limits VALIDATION PARAMETRES SYSTEM SUITABILITY: To verify the analytical system is working the system suitability parameters are to be set. Standard preparation 1: weighed 11.24 mg of Prasugrel HCL WS into 100ml volumetric flask, added 60 ml of diluents, to dissolved for about 10 minutes, further made up to volume with the diluents. Standard preparation 2: Weighed 11.32 mg of Prasugrel Hydrochloride into 100ml volumetric flask, added 60ml diluent and further diluted with the diluent up to 100ml of the volumetric flask. The results were tabulated in table 1 & 2. SPECIFICITY Standard preparation : weighed 11.76g of Prasugrel HCL into 100ml volumetric flask, add 60ml of diluent, to dissolve for 10 minutes. Further made up the volume up to 100 ml with diluent.fig-2 Impurity stock preparation: 2.53 mg of Desacetyl impurity was weighed into a 25 ml volumetric flask. 15 ml of the diluent was added, dissolved for 10 minutes and made up to volume with the diluent. Fig-3 Impurity spiked preparation: transferred 1ml of the standard stock solution and 1ml of impurity stock solution into 20 ml volumetric flask made up to the volume with the diluent. Fig-4 Placebo preparation: weighed 174.61 mg of the Prasugrel HCL 10 mg Placebo into 100ml volumetric flask, added 60ml of diluent, to dissolve for about 10 minutes and further make up to volume with the diluent. 0.45 m and the filtrate were used after the discarding of the first 5ml. Fig-5 LINEARITY Standard stock preparation: 10 mg of Prasugrel HCL was weighed into 50ml volumetric flask; 30 ml of the diluent was added, left for 10 minutes to dissolve. The volume was made such that it was 200mg/L. Further dilutions were made of different concentrations as below: Standard solution 50% preparation (50mg/L): diluted 2.50 ml of the standard stock preparation to 10ml with the diluent. Standard solution 75% preparation (75mg/L): diluted 3.75 ml of the standard stock preparation to 10 ml with the diluent. Standard solution 100% Preparation (100mg/L): Diluted 5.00 ml of the standard stock Preparation to 10 ml with diluent. 1134

Standard Solution 125% preparation (125mg/L): Diluted 6.25 ml of the standard stock preparation to 10ml with diluent. Standard Solution 150% preparation (150.0mg/L): Diluted 7.50mL of the standard stock preparation to 10ml with diluents. The results were tabulated in table 4 and Calibration curve for linearity is in fig -6. Table 3: Linearity S.No. Concentration in (mg/l) Area 1 50.0 1025654 2 75.0 1633205 Correlation Coefficient (r2) 3 100.0 2155933 should not be less than 4 125.0 2673659 0.999 5 150.0 3330221 Area Fig 6: Calibration curve for Linearity Linearity 4000000 3000000 2000000 1000000 0 3330221 2673659 2155933 1633205 1025654 50 75 100 125 150 Concentration PRECISION: Weighed 11.76mg of Prasugrel HCL into 100ml volumetric The standard solution was prepared and results were tabulated. Sample preparation -1: Sample preparation -2: 180.08mg of tablet powder were weighed and transferred Sample preparation -3: 180.18mg of tablet powder were weighed and transferred Sample preparation -4: 180.47mg of tablet powder were weighed and transferred Sample preparation -5: 181.27mg of tablet powder were weighed and transferred Sample preparation -6: 180.67mg of tablet powder were weighed and transferred The Prasugrel tablets were powdered and spiked and results were tabulated. ACCURACY: Weighed 11.32mg of Prasugrel HCL into 100ml volumetric Sample preparation 50% (50.0mg/L): 92.16mg of tablet powder were weighed and transferred 0.45µm. Sample preparation 75% (75.0mg/L): 143.82mg of tablet powder were weighed and transferred Sample preparation 100%(100.0mg/L): 183.49mg of tablet powder were weighed and transferred Sample preparation 125 %( 125.0mg/L): 230.40mg of tablet powder were weighed and transferred Sample preparation 150 %( 150.0mg/L): 291.59mg of tablet powder were weighed and transferred the results were tabulated in table 5a &5b. System suitability Theoretical plates for Prasugrel standard Tailing factor for Prasugrel Standard RSD for peak area of Pasugrel from 5 injections of the standard Table 5 a: Accuracy Observed values Criteria 4507 NLT 2500 1.43 NMT 2.0 0.08 NMT 2.0% 1135

Table 5 b: Accuracy data Sample No Spike µg/ml level added µg/ml found 1 50% 48.6 48.2 2 50% 48.6 48.1 3 50% 48.6 48.1 1 75% 76.1 79.1 2 75% 76.1 79.0 3 75% 76.1 79.1 1 100% 98.4 99.5 2 100% 98.4 99.5 3 100% 98.4 99.4 1 125% 126.2 123.9 2 125% 126.2 126.1 3 125% 126.2 125.9 1 150% 158.2 160.1 2 150% 158.2 160.1 3 150% 158.2 160.1 % Recovery 99.1 101.1 99.9 101.9 101.2 The accuracy (recovery) for the average of triplicate at each concentration level should be within 98.0% to 102.0% RUGGEDNESS: 1. Analysis with different analyst: Weighed 11.72mg of Prasugrel HCL into 100ml volumetric 183.23mg of tablet powder were weighed and transferred 0.45µm. 185.08mg of tablet powder were weighed and transferred Sample preparation 3: 186.82mg of tablet powder were weighed and transferred Sample preparation 4: 185.44mg of tablet powder were weighed and transferred Sample preparation 5: 181.27mg of tablet powder were weighed and transferred Sample preparation 6: 180.51mg of tablet powder were weighed and transferred The results were tabulated in table 6a1 &6a2. Table 6a1: System Precision System suitability Observed value Theoretical Plates for Prasugrel standard 8823 NLT 2500 Tailing factor for Prasugrel standard 1.31 NMT 2.0 RSD for peak area of Prasugrel from five injections 0.14 NMT 2.0% Table 6a2: Data for System Precision Sample % of Assay Number Analyst-1 Analyst-2 1 99.7 99.9 2 100.4 99.6 All-individual assays 3 99.2 98.7 of Prasugrel tablets 4 100.1 98.7 should be within 5 98.5 99.7 98.0% to 102.0% by 6 98.9 98.9 the analyst, columns Mean 99.4 99.3 and systems. % RSD 0.74 0.53 2. Solution stability: Standard preparation (Initial): Weighed 11.61mg of Prasugrel HCL into 100ml volumetric Standard preparation (12 th hour): 11.76mg of tablet powder were weighed and transferred 0.45µm. Standard preparation (24 th hour): 11.96mg of tablet powder were weighed and transferred Standard preparation (36 th hour): 11.42mg of tablet powder were weighed and transferred The results were tabulated in table 6b1. Table 6b1: Bench top stability %Assay of Standard % of Difference Time in Prasugrel (similarity hours Testfactor) Test-2 Test-3 Test-4 1 Initial NA 99.7 100.4 NA NA 12 th hour 1.003 100.4 100.9 0.7 0.5 24 th hour 0.997 100.8 101.6 1.1 1.2 36 th hour 1.001 101.0 101.8 1.3 1.4 Similarity factor between two Prasugrel standard preparations 0.985-1.015 Acceptable difference between initial and stability samples against fresh standard is NMT 3.0%. ROBUSTNESS: 1. Filter variation: Standard preparation : Weighed 11.61mg of Prasugrel HCL into 100ml volumetric 1136

0.45µm PTFE filter. 180.08mg of tablet powder were weighed and transferred the diluent and mixed. Filtered through 0.45µm Nylon filter. The results were tabulated in table 7. S.No. Table 7 a. Filter variation Flow Rate %RSD At 1.2ml At 1.4ml Std Areas Std Areas 1 2232059 1935847 2 2233969 1946697 3 2235380 1966582 4 2235410 1887082 5 2195067 1882595 AVG 2226377 1923761 SD 17556 37235 % RSD 0.53 1.94 Relative standard deviation for peak area of prasugrel from five injections of standard should not be more than 2.0% 2. Effect of variation in flow rate: Weighed 11.61mg of Prasugrel HCL into 100ml volumetric 5mL and inject into the system at a flow rate of 1.2mL. 5mL and inject into the system at a flow rate of 1.4mL.the results were tabulated in table 7b. Table 7 b. Effect of variation in flow rate % of Assay of Prasugrel as % of labelled amount Sample No 0.45µm 0.45µm % of Difference Nylon PTFE 1 99.7 100.1 0.4 2 100.4 98.6 1.8 3 99.2 97.4 1.8 The difference between the filtered sample solutions should not be more than 3.0% 3. Effect of variation in column temperature: Weighed 11.42mg of Prasugrel HCL into 100ml volumetric 5mL and maintain a column temperature of 25ºC. 5mL and maintain a column temperature of 30ºC. 5mL and maintain a column temperature of 35ºC. inject into the system at a flow rate of 1.4mL.the results were tabulated in table 7b. Table 7 c. Effect of variation in column temperature Temperature %RSD At 25 S.No. 0 At 30 0 At 35 0 Std Std Std Areas Areas Areas 1 2144313 2098262 2122540 Relative standard 2 2145023 2097886 2122996 deviation for peak 3 2138191 2097184 2121340 area of prasugrel from five 4 2138596 2094386 2118118 injections of 5 2141137 2094325 2113378 standard should not AVG 2141452 2096409 2119674 be more than 2.0% SD 3155 1914 4003 RSD 0.15 0.09 0.19 CONCLUSION A simple, rapid and reproducible RP-HPLC method was developed for the estimation of Prasugrel Hydrochloride in the tablet dosage form. The method was validated for system suitability, specificity, precision, accuracy, linearity, ruggedness and robustness. The conclusion is therefore that this method can be adopted as a method of analysis for Prasugrel Hydrochloride. REFERENCES 1. https://pubchem.ncbi.nlm.nih.gov/compound/prasugrel 2. H. Beckett, J.B. Stenlake, Practical Pharmaceutical Chemistry, 4 th Edition, C.B.S Publications, Pg85-157 3. Vijay Malik, Drugs and cosmetics Act 1940, 16 th Edition., Eastern Book Company, Lucknow. Pg No 5 1137

4. Instrumental methods of analysis, 7 th Edition., CBS Publishers, new Delhi. 5. Validation of Compendia Methods USP 1225 USPC Rockville Maryland USA 1994 6. International Conference of Harmonization Guidelines on validation of Analytical Procedures Definitions and Terminology Federal Register (March 1, 1995) 7. Method development and Validation for the HPLC potency assay of Prasugrel tablets. A ElphinePrabahar 1*, N. Rama Raol, K.R.S. Sambasiva Rao and P. Vijayaraj Kumar 8. Prasugrel: A review of its role in the management of Arterial Coronary Thrombosis. Marek Postula and Margaret M. Marczew 1138